Clinical Trials: Neuroblastoma

Duarte : City of Hope

COG ANBL00B1: Neuroblastoma Biology Studies

View More »

Los Angeles : Children's Hospital of Los Angeles

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

San Diego : Rady Children's Hospital

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

San Diego : Rady Children's Hospital

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Hartford : Connecticut Children's Hospital

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Hartford : Connecticut Children's Hospital

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Hartford : Connecticut Children's Hospital

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Orlando : Arnold Palmer Hospital for Children- MD Anderson

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Orlando : Arnold Palmer Hospital for Children- MD Anderson

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Orlando : Arnold Palmer Hospital for Children- MD Anderson

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Orlando : Arnold Palmer Hospital for Children- MD Anderson

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Savannah : Memorial University Medical Center

ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

View More »

Atlanta : Children's Healthcare of Atlanta Childern Hosp - ATL

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Baltimore : Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Boston : Dana Farber Cancer Institute DFCI (3)

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Boston : Dana-Farber Cancer Institute

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Ann Arbor : The University of Michigan Comprehensive Cancer Center

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

Grand Rapids : Helen DeVos Children's Hospital

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Grand Rapids : Helen DeVos Children's Hospital

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Grand Rapids : Helen DeVos Children's Hospital

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Grand Rapids : Helen DeVos Children's Hospital

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Minneapolis : Children's Hospitals and Clinics of Minnesota - Minneapolis

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Kansas : Children's Mercy Hospital (Kansas)

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Kansas City : Children's Mercy Hospitals and Clinics

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Kansas City : Children's Mercy Hospitals and Clinics

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Kansas City : Children's Mercy Hospitals and Clinics

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

St. Louis : Cardinal Glennon Children's Medical Center

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Bronx : Children's Hospital at Montefiore

A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer

New York : Memorial Sloan Kettering Cancer Center

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

New York : Memorial Sloan-Kettering Cancer Center

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Charlotte : Levine Children's Hospital

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Charlotte : Levine Children's Hospital

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Charlotte : Levine Children's Hospital

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Charlotte : Levine Children's Hospital

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation

¹³¹I-Metaiodobenzylguanidine (MIBG) with Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation

¹³¹I-MIBG Expanded Access: An Open Label, Expanded Access Protocol Using ¹³¹I-Metaiodobenzylguanidine (¹³¹I-MIBG) Therapy in Patients With Refractory Neuroblastoma

Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation

Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder In Patients with Recurrent or Resistant Neuroblastoma IND# 68,254

View More »

Cincinnati : Cincinnati Children's Hospital Medical Center

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

Pittsburgh : Children's Hospital of Pittsburgh

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Charleston : Medical University of South Carolina

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Fort Worth : Cook Children's Medical Center

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Houston : Texas Children's Hospital

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

Houston : Texas Children's Cancer and Hematology Centers

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Seattle : Seattle Children's Hospital CPKC412A2114

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Seattle : Seattle Children's

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Buenos Aires : Prof. Dr. J. P. Garrahan National Children's Hospital

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Parkville : Novartis Investigative Site

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Toronto : Novartis Investigative Site

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Lyon Cedex : Centre Léon Berard

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Paris : Institut Curie, Département de Pédiatrie

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Paris : Novartis Investigative Site

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Villejuif : Institut Gustave Roussy, Département de Pédiatrie

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Villejuif Cedex : Novartis Investigative Site

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Frankfurt : Hospital for Children and Adolescents II/III

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Freiburg : Klinik IV Pädiatrische Hämatologie, Onkologie Zentrum für Kinderheilkunde, Jugendmedizin UNIVERSITAT

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Hannover : Medizinische Hochschule Hannover

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Tübingen : Universitatslclinik fur Kininder-und Jugendmedizin

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Bologna : Novartis Investigative Site

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Genova : Gaslini Children's Hospital, Paediatric Haematology-Oncology Department

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Milano : Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Milano : Novartis Investigative Site

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Padova : Clinica di Oncoematologia Pediatrica, Dipartimento di Pediatria

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

View More »

Roma : Ospedale Pediatrico Bambin Gesù, Dipartimento di Oncoematologia Pediatrica

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Birmingham : Birmingham Children's Hospital NHS foundation

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Glasgow : Royal Hospital for Sick Children

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

London : Great Ormond Street Hospital for Children NHS Trust

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Newcastle Upon Tyne : Novartis Investigative Site

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Sutton : Royal Marsden Hospital, Haemato-Oncology Unit, Institute of Cancer Research

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

View More »

Sutton : Novartis Investigative Site

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB